199 related articles for article (PubMed ID: 35729339)
1. The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.
Zhang S; Gu C; Huang L; Wu H; Shi J; Zhang Z; Zhou Y; Zhou J; Gao Y; Liu J; Leng Y; Liu X; Zhang Q; Huang L; Tong X; Young KH; Li J; Zhu H; Zhang T
Sci Rep; 2022 Jun; 12(1):10488. PubMed ID: 35729339
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
Ramos CA; Ballard B; Zhang H; Dakhova O; Gee AP; Mei Z; Bilgi M; Wu MF; Liu H; Grilley B; Bollard CM; Chang BH; Rooney CM; Brenner MK; Heslop HE; Dotti G; Savoldo B
J Clin Invest; 2017 Sep; 127(9):3462-3471. PubMed ID: 28805662
[TBL] [Abstract][Full Text] [Related]
3. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
Guercio M; Orlando D; Di Cecca S; Sinibaldi M; Boffa I; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Bovetti K; Manni S; Caruana I; Ciccone R; Del Bufalo F; Merli P; Vinti L; Girardi K; Ruggeri A; De Stefanis C; Pezzullo M; Giorda E; Scarsella M; De Vito R; Barresi S; Ciolfi A; Tartaglia M; Moretta L; Locatelli F; Quintarelli C; De Angelis B
Haematologica; 2021 Apr; 106(4):987-999. PubMed ID: 32381575
[TBL] [Abstract][Full Text] [Related]
4. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas.
Muhsen IN; Hill LC; Ramos CA
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1107-1124. PubMed ID: 37357070
[TBL] [Abstract][Full Text] [Related]
6. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN
Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637
[TBL] [Abstract][Full Text] [Related]
7. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.
Di Stasi A; De Angelis B; Rooney CM; Zhang L; Mahendravada A; Foster AE; Heslop HE; Brenner MK; Dotti G; Savoldo B
Blood; 2009 Jun; 113(25):6392-402. PubMed ID: 19377047
[TBL] [Abstract][Full Text] [Related]
8. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb.
Wu Y; Chen D; Lu Y; Dong SC; Ma R; Tang WY; Wu JQ; Feng JF; Wu JZ
Cancer Gene Ther; 2022 Feb; 29(2):167-177. PubMed ID: 33514882
[TBL] [Abstract][Full Text] [Related]
9. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy.
Marques-Piubelli ML; Kim DH; Medeiros LJ; Lu W; Khan K; Gomez-Bolanos LI; Rodriguez S; Parra ER; Ok CY; Aradhya A; Solis LM; Nieto YL; Steiner R; Ahmed S; Vega F
Histopathology; 2023 Jul; 83(1):143-148. PubMed ID: 36994939
[TBL] [Abstract][Full Text] [Related]
10. Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30
Hombach AA; Rappl G; Abken H
Mol Ther; 2019 Oct; 27(10):1825-1835. PubMed ID: 31331813
[TBL] [Abstract][Full Text] [Related]
11. Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells.
Suzuki O; Hirsch B; Abe M; Dürkop H; Stein H
Lab Invest; 2012 Feb; 92(2):191-9. PubMed ID: 21986812
[TBL] [Abstract][Full Text] [Related]
12. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30
Hong LK; Chen Y; Smith CC; Montgomery SA; Vincent BG; Dotti G; Savoldo B
Cancer Immunol Res; 2018 Oct; 6(10):1274-1287. PubMed ID: 30087115
[TBL] [Abstract][Full Text] [Related]
13. Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma.
Alvarez-Fernández C; Escribà-Garcia L; Caballero AC; Escudero-López E; Ujaldón-Miró C; Montserrat-Torres R; Pujol-Fernández P; Sierra J; Briones J
Clin Transl Immunology; 2021; 10(4):e1268. PubMed ID: 33968404
[TBL] [Abstract][Full Text] [Related]
14. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
15. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma.
Voorhees TJ; Zhao B; Oldan J; Hucks G; Khandani A; Dittus C; Smith J; Morrison JK; Cheng CJ; Ivanova A; Park S; Shea TC; Beaven AW; Dotti G; Serody J; Savoldo B; Grover N
Blood Adv; 2022 Feb; 6(4):1255-1263. PubMed ID: 34666347
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer.
Parekh P; Kamble S; Zhao N; Zeng Z; Portier BP; Zu Y
Biomaterials; 2013 Nov; 34(35):8909-17. PubMed ID: 23968853
[TBL] [Abstract][Full Text] [Related]
17. Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies.
Kim DH; Vega F
Blood; 2022 Feb; 139(6):951. PubMed ID: 35142847
[No Abstract] [Full Text] [Related]
18. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
19. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
Brudno JN; Natrakul DA; Karrs J; Patel N; Maass-Moreno R; Ahlman MA; Mikkilineni L; Mann J; Stroncek DF; Highfill SL; Fromm GC; Patel R; Pittaluga S; Kochenderfer JN
Blood Adv; 2024 Feb; 8(3):802-814. PubMed ID: 37939262
[TBL] [Abstract][Full Text] [Related]
20. The value of anti-CD30 CAR T cells in Hodgkin lymphoma.
Veyri M
Lancet Haematol; 2024 May; 11(5):e314-e316. PubMed ID: 38555922
[No Abstract] [Full Text] [Related]
[Next] [New Search]
